Figure 2
XmAb5592 induces strong MM cell lysis by degranulation of NK cells even in the presence of BMSCs. (A) XmAb5592-mediated lysis against MM1S, MM1R, and INA-6 MM cells was measured by calcein-AM release ADCC assay, in the presence or absence of BMSCs. Data were obtained in triplicate and represent the mean ± SD. (B) MM1S target cells and NK effector cells were incubated with serial dilutions of antibodies in the presence and absence of BMSCs, followed by dual-color flow cytometry analysis to determine the percentage of CD107a+ NK cells. Data were obtained in triplicate and represent the mean ± SD. XmAb5592 induced ∼ 10-fold more NK degranulation than the IgG1 analog in a dose dependent manner, regardless of the presence of BMSCs. (C) Calcein-AM release based ADCC assay was simultaneously performed (as in panel B) for XmAb5592 and the IgG1 analog treatment groups, in the presence or absence of BMSCs.

XmAb5592 induces strong MM cell lysis by degranulation of NK cells even in the presence of BMSCs. (A) XmAb5592-mediated lysis against MM1S, MM1R, and INA-6 MM cells was measured by calcein-AM release ADCC assay, in the presence or absence of BMSCs. Data were obtained in triplicate and represent the mean ± SD. (B) MM1S target cells and NK effector cells were incubated with serial dilutions of antibodies in the presence and absence of BMSCs, followed by dual-color flow cytometry analysis to determine the percentage of CD107a+ NK cells. Data were obtained in triplicate and represent the mean ± SD. XmAb5592 induced ∼ 10-fold more NK degranulation than the IgG1 analog in a dose dependent manner, regardless of the presence of BMSCs. (C) Calcein-AM release based ADCC assay was simultaneously performed (as in panel B) for XmAb5592 and the IgG1 analog treatment groups, in the presence or absence of BMSCs.

Close Modal

or Create an Account

Close Modal
Close Modal